GlassScriptPhysician profile
Heather M Tyson
NPI 1609448539
$2,892.18
in general payments reported to CMS, 2019-2025
29 companies · $833 in 2025
The $833 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $311 · 2023: $880 · 2024: $868 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.80 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $630.99 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $227.02 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $218.69 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $217.29 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $200.88 | 2023-2025 | Farxiga, Airsupra, Evusheld |
| Neurocrine Biosciences, INC. | $167.20 | 2022-2025 | Ingrezza, Ongentys |
| Lucid Diagnostics INC. | $165.46 | 2023 | |
| Glaxosmithkline, LLC. | $161.24 | 2022-2025 | Trelegy Ellipta |
| Abbvie INC. | $157.33 | 2023-2025 | |
| Intuitive Surgical, INC. | $117.62 | 2023 | Da Vinci Surgical System |
| Lundbeck LLC | $77.63 | 2024-2025 | Rexulti |
| Alkermes, INC. | $62.89 | 2024-2025 | Aristada, Lybalvi |
| Ucb, INC. | $59.35 | 2022-2023 | Briviact |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.39 | 2023-2024 | Caplyta |
| Lilly USA, LLC | $47.53 | 2025 | Mounjaro, Zepbound |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $36.27 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $34.53 | 2022-2023 | |
| Amgen INC. | $33.95 | 2022-2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.83 | 2022 | |
| Boston Scientific Corporation | $27.59 | 2024 | Watchman Access System |
| Dexcom, INC. | $25.12 | 2024 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $23.07 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.33 | 2023 | |
| Corium, LLC | $19.63 | 2023 | Adlarity |
| E.R. Squibb & Sons, L.L.C. | $19.47 | 2025 | Cobenfy |
| Global Blood Therapeutics, INC. | $15.23 | 2022 | |
| Vivus LLC | $13.53 | 2022 | |
| Pfizer INC. | $12.76 | 2023 | |
| Inogen, INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.